October 9, 2024
Methotrexate (MTX) is a commonly used treatment option for managing refractory atopic dermatitis, especially as an alternative to cyclosporine, anti-interleukins, or anti-JAK treatments. According to the […]
October 8, 2024
AMSTERDAM — The investigational interleukin (IL)-17A inhibitor izokibep induces clear clinical responses in people with moderate to severe hidradenitis suppurativa (HS) within a few weeks of […]
October 8, 2024
AMSTERDAM — The Janus kinase inhibitor delgocitinib may be a better or comparable choice for treating hand eczema than some more established therapies, suggested the results […]
October 7, 2024
AMSTERDAM — Prurigo nodularis (PN), an itchy, highly symptomatic disease that can cause severe impairments in quality of life, may gain a third therapy if promising […]
October 7, 2024
TOPLINE: Crisugabalin — an oral calcium channel alpha 2 delta-1 subunit ligand — was safe and well-tolerated at doses of 40 mg/d and 80 mg/d and […]
October 7, 2024
TOPLINE: Eczematous dermatitis, folliculitis, and seborrheic dermatitis were the most common skin conditions in patients with Down syndrome (DS) in a 10-year retrospective review. METHODOLOGY: Researchers […]
October 4, 2024
HUNTINGTON BEACH, California — When patients of Aaron Mangold, MD, first learn they have mycosis fungoides (MF), the most common form of primary cutaneous T-cell lymphoma […]
October 4, 2024
TOPLINE: Temtokibart, a novel monoclonal antibody, appears to achieve clinical improvements in moderate to severe atopic dermatitis (AD) by normalizing the skin barrier and increasing hydration, […]
October 3, 2024
AMSTERDAM — Following the report of results from a randomized trial in which a topically applied Janus kinase (JAK) inhibitor was highly active in patients with […]